Related references
Note: Only part of the references are listed.Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)
Liang Xia et al.
CLINICAL CANCER RESEARCH (2022)
First-Line Immunotherapy for Non-Small-Cell Lung Cancer
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial
Howard Jack West et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 e PEARLS/KEYNOTE-091 study
L. Paz-Ares et al.
ANNALS OF ONCOLOGY (2022)
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non-Small Cell Lung Cancer
Jia-Tao Zhang et al.
CANCER DISCOVERY (2022)
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)
CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
E. B. Garon et al.
ANNALS OF ONCOLOGY (2022)
PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091
S. Peters et al.
ANNALS OF ONCOLOGY (2022)
PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase III Study of Atezolizumab vs Best Supportive Care in Resected NSCLC
H. Wakelee et al.
Journal of Thoracic Oncology (2022)
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Mary O'Brien et al.
LANCET ONCOLOGY (2022)
Neoadjuvant immunotherapy in non-small cell lung cancer: a narrative review on mechanisms, efficacy and safety
Lan Shao et al.
JOURNAL OF THORACIC DISEASE (2022)
Induction immune-checkpoint inhibitors for resectable oncogene-mutant NSCLC: A multicenter pooled analysis
Chao Zhang et al.
NPJ PRECISION ONCOLOGY (2022)
Neoadjuvant immunotherapy in non-small-cell lung cancer: a narrative review on mechanisms, efficacy and safety
Lan Shao et al.
JOURNAL OF THORACIC DISEASE (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes
Si-Yang Liu et al.
NATURE COMMUNICATIONS (2021)
Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art
Jin Kang et al.
CANCER COMMUNICATIONS (2021)
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
D. Rodriguez-Abreu et al.
ANNALS OF ONCOLOGY (2021)
Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future
Chun Ho Szeto et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
MERMAID-1: A Phase III Study of Adjuvant Durvalumab plus Chemotherapy in Resected NSCLC Patients with MRD plus Post-Surgery
S. Peters et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
MERMAID-2: Phase III study of durvalumab in patients with resected, stage II-III NSCLC who become MRD plus after curative-intent therapy
D. R. Spigel et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
Enriqueta Felip et al.
LANCET (2021)
Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC
Michael J. Grant et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial
Jianxing He et al.
LANCET RESPIRATORY MEDICINE (2021)
CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC).
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
Jacob Sands et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC
Roy S. Herbst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Current status of immune checkpoint inhibition in early-stage NSCLC
J. Vansteenkiste et al.
ANNALS OF ONCOLOGY (2019)
Immunotherapy in patients with early stage resectable nonsmall cell lung cancer
Katrien Ghysen et al.
CURRENT OPINION IN ONCOLOGY (2019)
Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades
Tao Lu et al.
CANCER MANAGEMENT AND RESEARCH (2019)
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies
Shetal A. Patel et al.
IMMUNITY (2018)
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study
Wen-Zhao Zhong et al.
LANCET ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
EA5142 adjuvant nivolumab in resected lung cancers (ANVIL).
Jamie E. Chaft et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN) a randomised, open-label, phase 2 trial
Dongsheng Yue et al.
LANCET RESPIRATORY MEDICINE (2018)
Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity
Orneala Bakos et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
Achim Rittmeyer et al.
LANCET (2017)
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Clinical Characteristics and Prognostic Factors in Bone Metastases from Lung Cancer
Li Zhang et al.
MEDICAL SCIENCE MONITOR (2017)
Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. E. Postmus et al.
ANNALS OF ONCOLOGY (2017)
Immunogenic cell death in cancer and infectious disease
Lorenzo Galluzzi et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
Peter Goldstraw et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan F. Vansteenkiste et al.
LANCET ONCOLOGY (2016)
Surgical Stress Abrogates Pre-Existing Protective T Cell Mediated Anti-Tumor Immunity Leading to Postoperative Cancer Recurrence
Abhirami A. Ananth et al.
PLOS ONE (2016)
EORTC-ETOP randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab versus placebo for patients with early stage non-small cell lung cancer (NSCLC) after resection and standard adjuvant chemotherapy: PEARLS (NCT02504372).
Mary E. R. O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
L. Apetoh et al.
ANNALS OF ONCOLOGY (2015)
Surgical trauma induces postoperative T-cell dysfunction in lung cancer patients through the programmed death-1 pathway
Pingbo Xu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
The incidence and clinical impact of bone metastases in non-small cell lung cancer
Michael Kuchuk et al.
LUNG CANCER (2015)
The Central Role of Arginine Catabolism in T-Cell Dysfunction and Increased Susceptibility to Infection After Physical Injury
Xinmei Zhu et al.
ANNALS OF SURGERY (2014)
Molecular Pathways: The Immunogenic Effects of Platinum-Based Chemotherapeutics
Stanleyson V. Hato et al.
CLINICAL CANCER RESEARCH (2014)
Copy number alteration burden predicts prostate cancer relapse
Haley Hieronymus et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Preventing Postoperative Metastatic Disease by Inhibiting Surgery-Induced Dysfunction in Natural Killer Cells
Lee-Hwa Tai et al.
CANCER RESEARCH (2013)
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
Wim H. J. Kruit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adjuvant MAGE-A3 Immunotherapy in Resected Non-Small-Cell Lung Cancer: Phase II Randomized Study Results
Johan Vansteenkiste et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Trauma equals danger-damage control by the immune system
Veit M. Stoecklein et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2012)
The Role of the Perioperative Period in Recurrence After Cancer Surgery
Antje Gottschalk et al.
ANESTHESIA AND ANALGESIA (2010)
Immune perturbations in patients along the perioperative period: Alterations in cell surface markers and leukocyte subtypes before and after surgery
Inbal Bartal et al.
BRAIN BEHAVIOR AND IMMUNITY (2010)
Lung Adjuvant Cisplatin Evaluation: A pooled analysis by the LACE collaborative group
Jean-Pierre Pignon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cancer care Ontario and American society of clinical oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non-small-cell lung cancer guideline
Katherine M. W. Pisters et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Vaccine-induced CD4+ T cell responses to MAGE-3 protein in lung cancer patients
D Atanackovic et al.
JOURNAL OF IMMUNOLOGY (2004)
Share Paper
